Brodie family office acquires Sur-Seal, an advanced materials specialist

Brodie Generational Capital Partners (BGCP), the single-family office of the Brodie family, has acquired Sur-Seal, LLC, a leading advanced materials converting and engineered solutions provider, from middle-market private equity firm Heartwood Partners. Sur-Seal, headquartered in Charlotte, North Carolina, engineers and manufactures highly customized components that address complex performance challenges including sealing, vibration and noise abatement, dust and liquid ingress protection, thermal management, and RFI/EMI shielding. The company serves customers across the electric vehicle, mobility, HVAC, medical, and industrial technology markets from manufacturing facilities in Charlotte, Cincinnati, and Grand Rapids. CEO Pete Futia and the existing management team will remain in place. During Heartwood’s ownership, Sur-Seal completed multiple strategic acquisitions — including Mueller Die Cut Solutions and Kent Manufacturing — that broadened its geographic footprint and materials science expertise. “Sur-Seal is exactly the type of business we set out to find,” said Jacob Brodie, President and COO of BGCP. “As a family office investing our own capital, we look for companies we want to own and grow for the long term.”

About Brodie Generational Capital Partners: The Purolite family office

Brodie Generational Capital Partners is a Radnor, Pennsylvania-based single-family office established in 2022 by the Brodie family following the $3.7 billion sale of Purolite Corporation to Ecolab in December 2021. Brothers Steve and Don Brodie founded Purolite in 1981 — sketching its first logo at Steve’s kitchen table and launching operations from Don’s basement — and grew it into one of the world’s leading manufacturers of ion-exchange resins used in water purification, pharmaceutical production, and semiconductor manufacturing. Steve Brodie, now in his eighties, serves as CEO of BGCP, while his son Jacob Brodie — formerly a vice president at Purolite — serves as President and COO. The family office invests its own permanent capital in high-quality middle-market businesses with a focus on specialty chemicals, manufacturing, aerospace and defense components, healthcare, and nuclear power, drawing inspiration from Berkshire Hathaway’s long-term ownership model. BGCP’s current portfolio includes Zahav Bioscience, a cancer therapy company developing gold nanoparticle-based treatments.

Picture Source: Unsplash+, Getty Images
Article Source: PR Newswire, 07.01.2026